attyloid’s sFIDA technology sheds light on the pathophysiological role of Aβ oligomers
We are very happy to announce that our latest research paper, titled “Aβ oligomers peak in early stages of Alzheimer’s disease preceding Tau pathology”, has been published in Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring (DADM).
Our research sheds light on the pivotal role of soluble Aβ oligomers in the development of Alzheimer’s disease (AD), focusing on their quantitative distribution and chronological sequence within the AD continuum. By analyzing 526 participants from the DELCODE study, our findings underscore the presence of Aβ oligomers peaking in early disease stages, specifically in individuals with subjective cognitive decline and mild cognitive impairment.
This study leverages attyloid’s proprietary sFIDA technology to measure Aβ and Tau oligomer titers in biofluids, presenting novel insights into the pathophysiology of AD. We extend our deepest gratitude to our collaborators across clinics, academia and industry. This achievement highlights the importance of our collective effort and the synergistic benefits of combining diverse expertise to advance our understanding and treatment of Alzheimer’s disease.